Welcome to Paras Biopharmaceuticals Finland Oy

Paras Biopharmaceuticals Finland is an acclaimed enabler of biopharmaceutical manufacturing technologies for biosimilars and long therapeutic peptides. Our facilities in Finland are dedicated to the development and scale-up of recombinant products, and are also equipped for future GMP production. We offer optimized scale-up technologies for products that have the potential for clinical and commercial manufacturing.

Paras’ work revolves around three main streams

1. Biosimilars comprised of osteoporosis teriparatide, analog insulins and therapeutic fragment of mAbs
2. High value recombinant enzymes such as Enterokinase (and other enzymes in pipeline).
3. Innovative Oncology molecule in partnership with an esteemed research institution.

Paras Biopharmaceuticals offers a unique combination of technologies and facilities to deliver biosimilars for the following areas: Osteoporosis, Rheumatoid Arthritis, Diabetes and Oncology. Paras has successfully developed a proprietaryTechnology platform and is now expanding its IPR by filing PCT patents. Together with Diabrid, Noblecleav, Biomultifold (which results in high scale-up production) and other proprietary technologies, Paras offers high yielding biosimilar technologies within biologic APIs.

Biomultifold® Microbial Expression Technology

Biomultifold® provides an innovative and highly efficient process for the production of recombinant proteins using an E. Coli expression system. Biomultifold® enables to achieve expression levels of multigrams of therapeutic proteins per liter of fermentation.

Paras NobleCleav® Technology

NobleCleav® is a proprietary technology for efficient processing of recombinant therapeutic peptides and therapeutic proteins. The technology facilitates high level production of authentic biologics by combining high specificity and activity of processing.

Key Highlights of our Core Strengths


Innovators of Diabrid NobleCleav® Technology...

Diabrid® Technology is a unique proprietary technology for the expression of recombinant therapeutic proteins and therapeutic peptides. The technology facilitates a higher expression of therapeutic proteins in a manner that enhances the quality and bio effectiveness of the molecules in addition to facilitating post production protocols.

Paras Biopharmaceuticals Finland Oy

Paras Biopharmaceuticals Finland Oy is an up-and-coming biopharmaceutical technology development company which has successfully developed the Diabrid Platform Technology proprietary for the high level expression of biosimilars in specially designed genetically stable clones.

Business and R&D Team

Company Presentation 2018

Company Presentation 2016

Company Presentation 2014

Company Presentation 2012

Latest News

Meet Us At


Paras Biopharmaceuticals Finland Oy offers a wide spectrum of biopharmaceuticals technologies for therapeutic peptides, proteins and process technologies.

Paras Biopharmaceuticals Finland Oy Offers

Diabrid® Technology
NobleCleav® Technology
Biomultifold® Technology
Oxidative Proteinfolding Technology

Photo Gallery

Connect with us

Paras Biopharmaceuticals
Finland Oy

Kiviharjunlenkki 10, OULU,
FI-90220 Finland

P: +358 442709462

Dr Ashesh Kumar
E: kumar.ashesh@parasbiopharma.com
P: +358 (0) 400207380

Dr Upendra Khurana
E: upendra.khurana@parasbiopharma.com
P:+358 (0) 449783160

Dr Mark Jackson
E: mark.jackson@parasbiopharma.com
P:+358 (0) 442905993

Skype: Paras.Finland